Hepion Pharmaceuticals, Inc.
HEPADrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How HEPA's past catalysts played out
rencofilstat, 75 mg
NASH With Fibrosis
Rencofilstat
Nonalcoholic Steatohepatitis (NASH)
CRV431 75mg
NASH - Nonalcoholic Steatohepatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rencofilstat, 75 mg | Phase 2 | NASH With Fibrosis | - | - |
Rencofilstat | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
CRV431 75mg | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Hepion Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Hepion Pharmaceuticals, Inc.'s (HEPA) pipeline across Phase 2. Its lead program is rencofilstat, 75 mg (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hepion Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Hepion Pharmaceuticals, Inc. (HEPA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HEPA biotech catalysts?→
Add HEPA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hepion Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.